← Back to headlines
Apogee Stock Declines After Phase 2 Results for Zumilokibart in Atopic Dermatitis
Apogee Therapeutics shares fell following the announcement of phase 2 clinical trial results for its drug zumilokibart, intended for the treatment of atopic dermatitis.
27 May, 17:13 — 27 May, 17:13
Sources
Showing 1 of 1 sources
